Adjuvant therapy of melanoma.

Adjuvant therapy of melanoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Adjuvant therapy of melanoma. Abstract Text:

Gaurav D Shah,Paul B Chapman,Gaurav D Shah,Paul B Chapman,

PURPOSE: The purpose of this article was to review the current state of knowledge regarding the efficacy of adjuvant therapy for melanoma. PATIENTS AND METHODS: We reviewed the published literature, focusing on randomized clinical trials. RESULTS: There have been no meaningful trials addressing adjuvant chemotherapy in melanoma because all trials have been underpowered. Adjuvant interferon-alpha has been tested both at high dose and at lower doses. None of the trials have shown a reproducible benefit in survival, although the high-dose trials and some of the low-dose trials have shown improvement in time to relapse. These experiences raise the question of whether chronic administration is more important than dose. An adjuvant pegylated interferon-alpha trial using a 5-year treatment period is currently under investigation. At least 7 randomized adjuvant vaccine trials have been published, but none have shown a beneficial effect on relapse-free or overall survival except in subset analyses. CONCLUSIONS: To date, no adjuvant therapy has resulted in improved overall survival. To be attractive as an adjuvant therapy, experience from other tumor types indicates that a chemotherapy regimen should have a response rate of at least 20% in metastatic melanoma. Currently, biochemotherapy is being tested as an adjuvant treatment but other, less toxic, regimens should be sought. Once such a regimen with acceptable toxicity is identified, it would be reasonable to test it as an adjuvant therapy in a properly powered randomized trial. High-dose interferon-alpha for 1 year remains the only U.S. Food and Drug Administration-approved adjuvant therapy for melanoma, but long-term chronic dosing of interferon-alpha may prove more effective than short-term dose schedules. Development of melanoma vaccines remains an appealing and important goal. New technologies and understanding of the immune response against melanoma are leading to novel vaccine strategies designed to break immunologic tolerance against melanoma.

Adjuvant therapy of melanoma. Publishing Authors By Initials

GD Shah,PB Chapman,GD Shah,PB Chapman,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Adjuvant therapy of melanoma. Journal Published:

PUBLICATION TYPE: Review

Journal: Cancer journal (Sudbury, Mass.)

VOLUME: 13

Page Numbers: 217-22

Journal Abbreviation:

ISSN: 1528-9117

DAY: 10

MONTH: 07

YEAR: 2007

Adjuvant therapy of melanoma. Information

Number of References: 56

LANGUAGE: eng

NlmUniqueID: 100931981

Adjuvant therapy of melanoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Adjuvant therapy of melanoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Adjuvant therapy of melanoma.

AFFILIATION: Department of Medicine, Melanoma/Sarcoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6007, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer J

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Adjuvant therapy of melanoma Related Publications

• Adjunctive Immunotherapy in Combination with Lipid-associated Amphotericin B for the Treatment of Invasive Candidiasis.
• Adjuvant therapy of melanoma.
• Autosomal dominant polycystic kidney disease: time for a change?
• Bandwidth and fidelity on the NEO-Five Factor Inventory: replicability and reliability of Saucier's (1998) item cluster subcomponents.
• Coil sensitivity estimation for optimal SNR reconstruction and intensity inhomogeneity correction in phased array MR imaging.
• Come to where the flavour is: additives and pesticide residue in cigarettes.
• Concepts and preliminary data toward the realization of image-guided liver surgery.
• Context effects on the spontaneous leg movements of infants with spina bifida.
• Control of coccidiosis into the next millennium.
• Curli biogenesis and function.
• Deterministic loading of individual atoms to a high-finesse optical cavity.
• Diffraction-enhanced imaging of a porcine eye.
• Effects of norgestomet, altrenogest, and/or estradiol on follicular and hormonal characteristics of late transitional mares.
• Employee participation in workplace health promotion and wellness programs: how important are incentives, and which work best?
• Evaluating the effectiveness of four contextual features in classifying annotated clinical conditions in emergency department reports.
• Examples of mathematical modeling: tales from the crypt.
• Falling prevalence of smoking: how low can we go?
• Haptic discrimination of two-dimensional angles: influence of exploratory strategy.
• High-throughput fluorescent multiplex array for indoor allergen exposure assessment.
• In vitro polymerization of a functional Escherichia coli amyloid protein.
• Interleukin-1beta is the primary initiator of pulmonary inflammation following liver injury in mice.
• Is "YouTube" telling or selling you something? Tobacco content on the YouTube video-sharing website.
• Lipidomics reveals that adiposomes store ether lipids and mediate phospholipid traffic.
• Neighborhood Walkability and Income: Associations with Walking for Leisure and Transportation: 644: May 31 8:45 AM 9:00 AM.
• Non-surgical embryo transfer and live birth in a llama.
• Primary aldosteronism in diabetic subjects with resistant hypertension.
• Spontaneous retinal activity mediates development of ocular dominance columns and binocular receptive fields in v1.
• Target Theory Revisited: Why Physicists are Essential for Radiobiology Research.
• The 9-hexadecenoic and 11-octadecenoic acid content of natural fats and oils.
• The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization.